Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion Therapeutics (GB:0IIM)
:0IIM
RESEARCH TOOLSreports
Holding GB:0IIM?
Track your performance easily
Earnings Data
Report Date
Feb 27, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 01, 2018
|% Change Since: -1.14%
|Next Earnings Date:Aug 02, 2018
Earnings Call Sentiment|Positive
Esperion has shown strong prescription growth and expanded payer access, both domestically and internationally. While facing some financial headwinds due to contract updates, the company is on track for future growth with a strengthened financial position.Company Guidance
During Esperion Therapeutics' Q3 2024 earnings call, CEO Sheldon Koenig highlighted the significant progress and guidance for the company's bempedoic acid products, NEXLETOL and NEXLIZET. The company reported a 10% sequential and 53% year-over-year increase in U.S. net product revenue, with prescriptions rising 12% and new-to-brand prescriptions up 18% compared to the prior quarter. They expanded coverage to 165 million patient lives, achieving over 65% Medicare and 92% commercial coverage. Internationally, they reported a 19% sequential increase in royalty revenue from Europe, and partners like Otsuka in Japan and Daiichi Sankyo in Taiwan are advancing approvals. Esperion is focused on sustaining this growth and expanding their global reach while preparing for further development of their ACLY inhibitors pipeline.Significant Prescription Growth
Esperion reported double-digit prescription growth for NEXLETOL and NEXLIZET, with a 53% year-over-year increase in U.S. net product revenue and a 10% sequential growth.
Expanded Payer Access
Updated utilization management criteria increased access to 165 million patient lives, with more than 65% Medicare and over 92% commercially insured lives covered.
International Expansion
Esperion's partner in Europe posted a 19% sequential increase in royalty revenue. Approval and launch activities in Taiwan and expected submissions in Canada, Australia, and Israel signal global growth potential.
Financial Strengthening
Esperion monetized European royalties and paid off a previous revenue interest facility, strengthening the balance sheet. Total revenue increased to $51.6 million from $34 million in Q3 2023.
---
GB:0IIM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
GB:0IIM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $2.19 | $2.12 | -3.20% |
| Aug 12, 2024 | $2.04 | $1.88 | -8.17% |
| May 07, 2024 | $2.08 | $2.44 | +17.59% |
| Feb 27, 2024 | $2.69 | $2.98 | +10.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Esperion Therapeutics (GB:0IIM) report earnings?
Esperion Therapeutics (GB:0IIM) is schdueled to report earning on Feb 27, 2025, TBA Not Confirmed.
What is Esperion Therapeutics (GB:0IIM) earnings time?
Esperion Therapeutics (GB:0IIM) earnings time is at Feb 27, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Esperion Therapeutics stock?
The P/E ratio of Esperion Therapeutics is N/A.
What is GB:0IIM EPS forecast?
GB:0IIM EPS forecast for the fiscal quarter 2024 (Q4) is -0.14.
---